Css LLC 89bio, Inc. Call Options Transaction History

Css LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $16,610 - $38,500	5,500 Added 37.93%	20,000 $116,000
Q2 2022 Aug 15, 2022	SELL	$2.09 - $4.02 $164,065 - $315,569	-78,500 Reduced 84.41%	14,500 $46,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $251,850 - $1.09 Million	73,000 Added 365.0%	93,000 $350,000
Q4 2021 Feb 14, 2022	BUY	$11.15 - $19.66 $223,000 - $393,200	20,000 New	20,000 $261,000

167

109M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $532M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

Stay updated on Css LLC with notifications on news.